KPV is a three-amino-acid peptide - lysine, proline, valine - taken from the tail end of alpha-melanocyte-stimulating hormone (α-MSH). It is studied for its anti-inflammatory activity in cell and animal models, and it is one of the four compounds in the KLOW research blend. This guide covers what KPV is, what the main studies tested, and what that evidence can and cannot tell you about a blend.
Evidence in one line: the published KPV work is preclinical - cell cultures and mouse models of intestinal inflammation. It is not an approved medicine, and findings for KPV on its own are not evidence about any blend that contains it.
What KPV is
α-MSH is a 13-amino-acid hormone made from a larger precursor protein, proopiomelanocortin. Besides its role in pigmentation, α-MSH has well-described anti-inflammatory effects, acting on pathways such as NF-κB activation and the production of pro-inflammatory cytokines. KPV is its C-terminal tripeptide - positions 11 to 13, written α-MSH(11-13) - and it has been studied as a much smaller fragment that keeps some of that anti-inflammatory activity.
| KPV at a glance | |
|---|---|
| Sequence | Lys-Pro-Val (K-P-V), 3 amino acids |
| Origin | C-terminal fragment of α-MSH, residues 11-13 |
| Main research area | Intestinal inflammation models (cells and mice) |
| Proposed mechanism | Uptake by the PepT1 transporter, then reduced NF-κB and MAP-kinase signalling |
| Clinical evidence | None established; not approved as a medicine |
What the main studies tested
Dalmasso and colleagues, Gastroenterology, 2008. The group asked whether KPV's anti-inflammatory effect depends on PepT1, a transporter for di- and tripeptides that is normally found in the small intestine and becomes expressed in the colon during inflammatory bowel disease. In human intestinal epithelial cells and T cells stimulated with pro-inflammatory cytokines, nanomolar KPV reduced NF-κB and MAP-kinase signalling and cytokine secretion, and the effect depended on PepT1. In two chemically induced mouse colitis models, KPV given in drinking water reduced the severity of colitis and the expression of inflammatory cytokines. The authors reported that the effect was PepT1-mediated rather than acting through melanocortin receptors.1
Kannengiesser and colleagues, Inflammatory Bowel Diseases, 2008. This study tested KPV in two mouse models - DSS colitis and T-cell transfer colitis - and in mice lacking a functional melanocortin-1 receptor. KPV-treated mice recovered earlier, with fewer inflammatory infiltrates in colon tissue and lower myeloperoxidase activity, a marker of neutrophil activity. The effect was also seen in the receptor-deficient mice.2
A broader review of α-MSH-related peptides, by Luger and Brzoska, places KPV within a family of small melanocortin fragments studied as anti-inflammatory and immunomodulating agents.3
How strong is the evidence?
- Preclinical only. The core studies are in cultured cells and mice. Results in mouse colitis models do not establish effects in any other setting.
- A narrow focus. Most of the work concerns intestinal inflammation, so findings outside that area are thin.
- Small number of groups. The key papers come from a handful of laboratories; independent replication matters.
KPV inside KLOW
KLOW is a four-compound research blend: GHK-Cu, BPC-157, TB-500 and KPV in one vial. Each component has its own literature, but there is no published body of evidence on the four together. That distinction matters when reading about blends:
- Component evidence is not blend evidence. A finding for KPV alone says nothing about how it behaves alongside three other peptides in the same solution.
- Amounts differ. The amount of each component in a blend is not the amount used in the single-compound studies, so results cannot be carried across.
- Interactions are untested. Whether the components affect each other's stability or activity is itself a research question.
For the two best-known KLOW components, see BPC-157 vs TB-500.
Handling
KPV and KLOW are supplied lyophilized. Follow the product's data sheet for diluent and storage, and see how to reconstitute peptides and how to store them. Supplier solubility guides suggest trying water first for very short peptides (under six residues) such as KPV; the solubility guide covers what to do when a peptide does not.
Frequently asked questions
What is KPV?
A tripeptide, lysine-proline-valine, that is the C-terminal sequence (residues 11-13) of alpha-melanocyte-stimulating hormone. It is studied for anti-inflammatory activity in cell and animal models.
Is there clinical evidence for KPV?
No established clinical evidence. The main published studies are in cultured cells and mouse models of intestinal inflammation, and KPV is not an approved medicine.
Does KPV research apply to KLOW?
Not directly. KLOW combines KPV with GHK-Cu, BPC-157 and TB-500, and findings for KPV alone are not evidence about how the four behave together.
Sources
- Dalmasso et al. - PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation, Gastroenterology 2008 (PMC)
- Kannengiesser et al. - Melanocortin-derived tripeptide KPV in murine models of IBD, Inflamm Bowel Dis 2008 (PubMed)
- Luger and Brzoska - alpha-MSH related peptides as anti-inflammatory agents, Ann Rheum Dis 2007 (PubMed)
Research use only. All products sold by Moleano Peptides are intended solely for laboratory research. They are not for human or veterinary use and are not drugs, supplements or medical devices. This guide is educational and is not medical advice.